BRPI0908421A2 - Suloção estável de um composto farmacêutico - Google Patents

Suloção estável de um composto farmacêutico

Info

Publication number
BRPI0908421A2
BRPI0908421A2 BRPI0908421-5A BRPI0908421A BRPI0908421A2 BR PI0908421 A2 BRPI0908421 A2 BR PI0908421A2 BR PI0908421 A BRPI0908421 A BR PI0908421A BR PI0908421 A2 BRPI0908421 A2 BR PI0908421A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compound
stable suction
suction
stable
pharmaceutical
Prior art date
Application number
BRPI0908421-5A
Other languages
English (en)
Inventor
Eric Schenkel
Claire Poulain
Betrand Dodelet
Domenico Fanara
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39643757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0908421(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of BRPI0908421A2 publication Critical patent/BRPI0908421A2/pt
Publication of BRPI0908421B1 publication Critical patent/BRPI0908421B1/pt
Publication of BRPI0908421B8 publication Critical patent/BRPI0908421B8/pt
Publication of BRPI0908421C1 publication Critical patent/BRPI0908421C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
BRPI0908421A 2008-03-03 2009-03-02 solução estável de um composto farmacêutico BRPI0908421C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08003915 2008-03-03
EP08003715.9 2008-03-03
PCT/EP2009/052454 WO2009109547A1 (en) 2008-03-03 2009-03-02 Pharmaceutical solutions, process of preparation and therapeutic uses

Publications (4)

Publication Number Publication Date
BRPI0908421A2 true BRPI0908421A2 (pt) 2015-08-04
BRPI0908421B1 BRPI0908421B1 (pt) 2020-08-04
BRPI0908421B8 BRPI0908421B8 (pt) 2020-08-18
BRPI0908421C1 BRPI0908421C1 (pt) 2021-05-25

Family

ID=39643757

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908421A BRPI0908421C1 (pt) 2008-03-03 2009-03-02 solução estável de um composto farmacêutico

Country Status (20)

Country Link
US (1) US20110021786A1 (pt)
EP (1) EP2273975B8 (pt)
JP (6) JP2011513360A (pt)
KR (1) KR101353425B1 (pt)
CN (1) CN101945647B (pt)
AU (1) AU2009221177B2 (pt)
BR (1) BRPI0908421C1 (pt)
CA (1) CA2715685C (pt)
CY (1) CY1115254T1 (pt)
DK (1) DK2273975T3 (pt)
EA (1) EA018736B1 (pt)
ES (1) ES2474945T3 (pt)
HR (1) HRP20140634T1 (pt)
IL (1) IL207558A (pt)
MX (1) MX2010009222A (pt)
PL (1) PL2273975T3 (pt)
PT (1) PT2273975E (pt)
RS (1) RS53418B (pt)
SI (1) SI2273975T1 (pt)
WO (1) WO2009109547A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2273975E (pt) * 2008-03-03 2014-07-17 Ucb Pharma Sa Processos de preparação e utilizações terapêuticas de soluções farmacêuticas
DK2346500T3 (en) * 2008-10-16 2017-07-17 Univ Johns Hopkins Methods and compositions for improving cognitive function
PT3106463T (pt) 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
PT2358361T (pt) * 2008-11-18 2016-11-18 Ucb Biopharma Sprl Formulações de libertação prolongada compreendendo um derivado de 2-oxo-1-pirrolidina
DK2790695T3 (en) 2011-12-16 2016-04-18 Uni Pharma Kleon Tsetis Pharmaceutical Lab S A A pharmaceutical composition comprising (S) -2- (2-oxopyrrolidin-1-yl) butanamide
CN102525900A (zh) * 2012-01-19 2012-07-04 南京恒道医药科技有限公司 左乙拉西坦注射液及其制备方法
JP2015515480A (ja) * 2012-04-19 2015-05-28 シー・アール・バード・インコーポレーテッドＣ Ｒ Ｂａｒｄ Ｉｎｃｏｒｐｏｒａｔｅｄ エチレンオキシド滅菌下のｐＨ安定性が改善された注入液
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN103550143B (zh) * 2013-10-19 2019-05-14 浙江华海药业股份有限公司 一种左乙拉西坦注射液的制备方法
MX384391B (es) 2015-05-22 2025-03-14 Agenebio Inc Composiciones farmacéuticas de levetiracetam de liberación extendida.
CN109069480A (zh) 2015-12-30 2018-12-21 阿达玛斯医药公司 用于治疗与癫痫相关的病症的方法和组合物
IL304018A (en) * 2016-04-04 2023-08-01 Loxo Oncology Inc Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2952056T3 (es) 2016-05-18 2023-10-26 Loxo Oncology Inc Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
CN106491523A (zh) * 2016-09-24 2017-03-15 北京万全德众医药生物技术有限公司 一种布瓦西坦口服溶液及其制备方法
WO2020021372A1 (en) * 2018-07-24 2020-01-30 Zenvision Pharma Llp Nasal drug delivery system of brivaracetam or salt thereof thereof
US20210393588A1 (en) * 2018-11-02 2021-12-23 Zenvision Pharma Llp Ready to use intravenous infusion of brivaracetam or salt thereof
JP7459868B2 (ja) 2019-03-28 2024-04-02 東洋紡株式会社 反射防止用円偏光板およびそれを用いた画像表示装置
CN113908120A (zh) * 2021-09-30 2022-01-11 北京诺康达医药科技股份有限公司 布立西坦药物溶液及其制备方法
CN116265011A (zh) * 2021-12-17 2023-06-20 北京万全德众医药生物技术有限公司 布瓦西坦口服液制备及其制备方法
CN114213306A (zh) * 2021-12-28 2022-03-22 海南鑫开源医药科技有限公司 一种布瓦西坦酸杂质的制备方法
CN116687843B (zh) * 2022-12-16 2026-03-20 中国人民解放军军事科学院军事医学研究院 一种高稳定性的布瓦西坦溶液及其制备方法和其应用
EP4505995A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. Oral solution composition comprising brivaracetam
EP4505994A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. Oral solution formulation comprising brivaracetam
TR2023009659A2 (tr) * 2023-08-11 2023-10-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bri̇varasetam i̇çeren bi̇r oral solüsyon
EP4505996A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. An oral solution comprising brivaracetam
EP4603081A1 (en) 2024-02-19 2025-08-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi An injectable composition of brivaracetam
CN118986873B (zh) * 2024-08-19 2025-10-14 海南卫康制药(潜山)有限公司 一种布立西坦溶液的制备方法及其布立西坦溶液

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
WO2005121082A1 (en) * 2004-06-11 2005-12-22 Ucb, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
PT2273975E (pt) * 2008-03-03 2014-07-17 Ucb Pharma Sa Processos de preparação e utilizações terapêuticas de soluções farmacêuticas
KR101286540B1 (ko) * 2008-04-16 2013-07-17 엘지디스플레이 주식회사 액정표시장치

Also Published As

Publication number Publication date
CA2715685A1 (en) 2009-09-11
EP2273975B1 (en) 2014-04-09
KR101353425B1 (ko) 2014-02-18
EA201001402A1 (ru) 2011-06-30
DK2273975T3 (da) 2014-06-30
IL207558A (en) 2015-02-26
JP2020128384A (ja) 2020-08-27
AU2009221177A1 (en) 2009-09-11
BRPI0908421B8 (pt) 2020-08-18
EP2273975A1 (en) 2011-01-19
MX2010009222A (es) 2010-09-28
PL2273975T3 (pl) 2014-09-30
HK1148202A1 (en) 2011-09-02
CN101945647A (zh) 2011-01-12
JP2019089837A (ja) 2019-06-13
SI2273975T1 (sl) 2014-09-30
ES2474945T3 (es) 2014-07-10
IL207558A0 (en) 2010-12-30
AU2009221177B2 (en) 2013-05-30
EA018736B1 (ru) 2013-10-30
BRPI0908421B1 (pt) 2020-08-04
JP2011513360A (ja) 2011-04-28
WO2009109547A1 (en) 2009-09-11
PT2273975E (pt) 2014-07-17
JP2015145382A (ja) 2015-08-13
EP2273975B8 (en) 2014-12-17
CY1115254T1 (el) 2017-01-04
JP2017114890A (ja) 2017-06-29
HRP20140634T1 (hr) 2014-11-21
BRPI0908421C1 (pt) 2021-05-25
CA2715685C (en) 2015-04-28
JP2022169734A (ja) 2022-11-09
RS53418B (sr) 2014-12-31
CN101945647B (zh) 2013-01-09
US20110021786A1 (en) 2011-01-27
KR20100126466A (ko) 2010-12-01

Similar Documents

Publication Publication Date Title
BRPI0908421A2 (pt) Suloção estável de um composto farmacêutico
CY2017026I1 (el) Τετρακυκλικη ενωση
BRPI1012247A2 (pt) compostos inseticidas
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI1015931A2 (pt) Compostos inseticidas
EP2419097A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2451274A4 (en) Pharmaceutical compositions
HRP20190509T1 (hr) Spoj piridilaminooctene kiseline
BRPI0917369A2 (pt) Compostos inseticidas
BRPI0918500A2 (pt) compostos inseticidas
BRPI0917188A2 (pt) Compostos inseticidas
LT3061445T (lt) Labai koncentruotos farmacinės kompozicijos
DK2041139T3 (da) Farmaceutiske forbindelser
BRPI0920521A2 (pt) combinação farmacêutica
BRPI0920514A2 (pt) infusão de fármacos
BRPI1013868A2 (pt) composto diaciletilenodiamina
BRPI0918602A2 (pt) composto (i)
BRPI1007017A2 (pt) uso de um composto.
BRPI0906098A2 (pt) Método de preparação de um composto
PT2260053E (pt) Análogos de oxitocina
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
DK3005986T3 (da) Infusion af lægemidler
BRPI0921654A2 (pt) formulação farmacêutica
BRPI1013941A2 (pt) compostos inseticidas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: UCB BIOPHARMA SPRL (BE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UCB BIOPHARMA SRL (BE)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2587 DE 04/08/2020 QUANTO AO INVENTOR E A PRIORIDADE UNIONISTA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF